41 results about "Intimal hyperplasia" patented technology

The invention provides a drug sustained release preparation for inhibiting vascular intimal hyperplasia and a preparation method and application thereof, and belongs to the technical field of biological medicine and vascular surgery. The drug sustained release preparation for inhibiting vascular intimal hyperplasia comprises a temperature-sensitive high polymer material and an MRTF / SRF pathway inhibitor, the temperature-sensitive high polymer material is a Pluronic type triblock copolymer; and the effective component of the MRTF / SRF pathway inhibitor is CCG222740 or CCG203971. The invention further discloses a preparation method of the MRTF / SRF pathway inhibitor. The drug sustained release preparation for inhibiting the vascular intimal hyperplasia can continuously release the MRTF / SRF pathway inhibitor at a fixed point in the AVF and other vascular injury repair process, can reduce at least 50% of neointimal area and vascular intimal-intimal thickness, and effectively inhibits the intimal hyperplasia.

The invention belongs to the technical field of medical instruments, and particularly relates to an intracranial drug balloon catheter and a preparation method thereof. A two-time spraying method is adopted, the humidity of carrier gas during two-time spraying is controlled, an amorphous-state drug coating and a crystalline-state combined drug coating are formed on the surface of the balloon catheter, and the drug can be released, permeated and stored within 90 s after the balloon catheter adheres to the wall; further, the technical effects of effectively and lastingly inhibiting the intimal hyperplasia and reducing the restenosis rate are achieved, and the method has excellent trafficability and traceability and can adapt to the complex environment condition of intracranial tortuous blood vessels; meanwhile, the drug coating firmness and release performance can be achieved at the same time, and neurotoxic complications caused by drug falling during in vitro, delivery and expansion are avoided.

This invention discloses the application of MYDGF in pharmaceuticals and medical devices for treating vascular intimal hyperplasia, belonging to the field of pharmaceutical technology. This invention utilizes MYDGF as a target in the preparation of products for protecting vascular function, and applies MYDGF in the preparation of drugs for treating vascular intimal hyperplasia, drugs for metabolic disorders related to vascular intimal hyperplasia, and medical devices for treating vascular intimal hyperplasia. This invention provides new candidate drugs and protein therapies for the clinical treatment of intimal hyperplasia.

The invention discloses a modified silk fibroin artificial blood vessel and a preparation method and application thereof.The modified silk fibroin artificial blood vessel comprises a modified silk fibroin composite scaffold and a polyurethane layer, the polyurethane layer is arranged on the modified silk fibroin composite scaffold through electrostatic spinning, and the polyurethane layer is prepared from polyurethane, the modified silk fibroin composite scaffold is prepared from the following raw materials: modified silk fibroin, arginine-glycine-aspartic acid polypeptide modified polycaprolactone, bacterial cellulose, a growth factor and glutaraldehyde. The modified silk fibroin is in bridge connection with the arginine-glycine-aspartic acid polypeptide modified polycaprolactone and is loaded with the growth factor. The comprehensive biocompatibility of the artificial blood vessel can be improved, thrombosis and intimal hyperplasia are effectively inhibited, and therefore the long-term patency rate of the small-caliber artificial blood vessel is greatly increased.

The invention provides a preparation method of a stent surface coating and a prepared coating stent. The preparation method comprises the following steps: s1, carrying out hydroxylation treatment on the stent base material; step s2, carrying out amino silanization treatment on the bracket base material subjected to hydroxylation treatment; s3, grafting a zwitterionic polymer on the inner surface of the stent base material subjected to amino silanization treatment to obtain an anti-coagulation coating; s4, the outer surface of the stent base material subjected to amino silanization treatment is coated with an anti-hyperplasia drug solution, and an anti-hyperplasia coating is obtained; wherein the anti-hyperplasia drug solution contains an anti-hyperplasia drug and a solvent, and the solvent is a long-chain polymer with an ester bond. The coated stent provided by the invention has the functions of anticoagulation and intimal hyperplasia inhibition at the same time.

This invention discloses a 3D-printed helical biodegradable anti-inflammatory vascular stent and its preparation method, belonging to the field of vascular stents. The invention uses multiple helical support wires arranged into a tubular shape, with the ends connected in a serpentine transitional manner. The helical support wires are connected by connecting ribs, and the surface is coated. This invention is biodegradable after use, avoiding the harm caused by permanent retention in the body, and has a lower restenosis rate compared to metal stents. The surface of the vascular stent is coated with a spermidine-containing coating to prevent immune rejection of the implanted vascular stent, thereby addressing the problems of inflammation and intimal hyperplasia. The helical structure facilitates contraction and expansion, has good bending flexibility, and the added connecting ribs increase the radial support performance of the vascular stent, better achieving the effect of vascular remodeling. This invention has significant implications in terms of biodegradability, anti-immune rejection, and mechanical properties, and can be used for treatment in different locations such as peripheral and coronary vessels.

The invention discloses a left iliac total vein extravascular stent and an operation method, and belongs to the field of medical instruments. The stent comprises a middle section connecting sleeve frame, an inferior vena cava sleeve frame and a left iliac vein sleeve frame which are integrally formed, the included angle between the three is 135-145 degrees, an elastic silica gel limiting clamping belt is arranged and made of a silicon rubber material, and the crosslinking density and flexibility are regulated and controlled by adjusting the vinyl content. The surgical method comprises the following steps of: minimally invasive laparoscopic approach, implanting a stent after exposing a target blood vessel, and adjusting the position. Direct contact between the built-in stent and the intima is avoided, the intima hyperplasia and thrombus risks are reduced, fatigue resistance and creep resistance are achieved, the stent is attached to the anatomical structure, fixation is stable, minimally invasive recovery is fast, customizable adaptation can be achieved, and the clinical treatment effect and safety are improved.

The present invention belongs to the field of medical devices, and specifically relates to a convex double-layer composite small-caliber artificial blood vessel and a preparation method thereof. The convex double-layer composite small-caliber artificial blood vessel includes an inner lining layer, an artificial blood vessel inner layer and an artificial blood vessel outer layer; the inner lining layer is made of a soluble material, and the middle part of the inner lining layer bulges radially outward; the artificial blood vessel inner layer and the artificial blood vessel outer layer are sequentially arranged outside the inner lining layer, and present a shape in which the middle part bulges radially outward under the support of the inner lining layer; the artificial blood vessel outer layer is a porous loose structure. The small-caliber artificial blood vessel of the present invention has a two-layer structure and is convex in shape. The combination of the dip coating layer and the electrospinning layer is beneficial to ensuring the suture retention strength and bursting pressure of the blood vessel, and can also enable the blood vessel to maintain a certain elasticity and porosity; the convex shape can make up for the lack of compliance of the artificial blood vessel, and is beneficial to reducing blood flow disturbance at the anastomosis, thereby reducing the risk of intimal hyperplasia.

The invention relates to the technical field of biological medicine and tissue engineering, in particular to a tissue engineering blood vessel and a preparation method and application thereof. The tissue engineering blood vessel is obtained by modifying interleukin 24 (IL-24) on the surface of an acellular blood vessel, after the tissue engineering blood vessel is transplanted into a body, the number of CD31 + and CD34 + cells can be remarkably increased, and infiltration of M2 type macrophages (CD163 +) on the surface of the blood vessel is remarkably increased; the expression of HIF-1 alpha (hypoxia marker) and MMP9 is obviously reduced; the expression of the nerve specific protein S-100 is obviously increased, thrombosis and intimal hyperplasia are effectively inhibited, and the patency rate of transplanted blood vessels is obviously increased.

The invention provides a grid support and a method for preparing a surface coating of the grid support, and the method comprises the following steps: preparing the grid support, and carrying out hydroxylation treatment on the surface of the grid support; the method comprises the following steps: grafting a phosphorylcholine copolymer on a hydroxylated grid stent, and carrying out cross-linking, so as to obtain an anticoagulant coating formed by modifying the cross-linked phosphorylcholine copolymer on the surface of the grid stent; and after the anti-coagulation coating is formed, coating at least part of the surface of the grid stent with the anti-hyperplasia drug coating. By means of the configuration, the grid support has the double effects of anticoagulation and intimal hyperplasia inhibition, the binding force between the coating and the substrate is further enhanced, and the coating is not prone to falling off.

The utility model relates to a recoverable inferior vena cava filter which comprises a recovery column and a vena cava filter body with an unfolded state and a folded state, a recovery hook is arranged on the recovery column, and the vena cava filter body comprises a plurality of first filter rods and a plurality of second filter rods; the first filter rod comprises a first sub-rod, a second sub-rod and a third sub-rod, the top end of the first sub-rod is connected with the recovery column, the tail end of the first sub-rod is connected with the top ends of the second sub-rod and the third sub-rod respectively, and first positioning hooks are arranged at the tail ends of the second sub-rod and the third sub-rod respectively; the top end of the second filter rod is connected with the recovery column, and the tail end of the second filter rod is provided with a second positioning hook. The problems that a traditional umbrella-shaped filter is low in capture rate, prone to deviation and poor in centering performance are solved, double-layer circumferential point contact is adopted to be fixedly attached to the blood vessel wall, good centering performance is guaranteed, and the problems that a traditional cylindrical supporting rod is large in contact area, intimal hyperplasia is likely to be caused, and the filter is difficult to recycle are solved.

The invention provides a means for prevention and adjuvant therapy of pulmonary vein stenosis, and particularly provides application of valsartan in preparation of drugs for prevention and adjuvant therapy of pulmonary vein stenosis. The valsartan can slow down the progress of intimal hyperplasia by inhibiting TGF-beta related pathways, so that the probability of occurrence of pulmonary vein stenosis is reduced. Therefore, the fusion protein can be used as an auxiliary treatment for surgical intervention, especially for preventing or treating acquired pulmonary vein stenosis after a complete pulmonary vein abnormal junction operation of children, and can reduce the occurrence probability of the acquired pulmonary vein stenosis after the operation and improve prognosis.

The invention belongs to the technical field of biomedical composite materials, and discloses a copper-based MOF modified small-caliber polyurethane artificial blood vessel and a preparation method. The copper-based metal organic framework is used as a functional carrier to be compounded with polyurethane, the artificial blood vessel with the inner diameter smaller than or equal to 6 mm is prepared through the electrostatic spinning technology, and synergistic release of copper ions, nitric oxide and medicine molecules is achieved; the preparation process comprises the steps of synthesis of the copper-based metal organic framework, preparation of a polyurethane solution, drug loading, electrostatic spinning forming and the like. According to the invention, a mechanical adaptation-biological regulation synergistic system is innovatively constructed, so that proliferation of endothelial cells is effectively promoted, excessive proliferation of smooth muscle cells is inhibited, and an ideal microenvironment is provided for vascular repair; the clinical problems of mechanical property mismatch, thrombosis, intimal hyperplasia and the like of the small-caliber artificial blood vessel are solved, and the preparation method is stable in process and low in cost and has important clinical application value.

The application relates to the field of biological medicine, in particular to a medicine for preventing intimal hyperplasia and application thereof, and specifically discloses application of a plasmid in preparation of a medicine for preventing intimal hyperplasia through extra-vascular injection, wherein the plasmid is one or more of HGF plasmid, VEGF plasmid and eNOS plasmid, and the plasmid is a naked plasmid. Through the scheme, a medicine of a safe, simple, efficient and local continuous expression gene delivery mode is developed, the medicine is precisely delivered from outside to inside through an extra-vascular injection path, the problems of easy loss of intraluminal medicine and poor targeting of systemic administration are solved, and the treatment effect of the disease is greatly improved.

The invention discloses application of nuclear receptor binding protein 2 in treatment of postoperative restenosis neointimal hyperplasia. The overexpressed nuclear receptor binding protein 2 can inhibit phenotypic transformation of vascular smooth muscle cells caused by platelet-derived growth factors (PDGF-BB) and enhancement of proliferation and migration capabilities. In addition, mouse carotid artery neointimal hyperplasia caused by carotid artery guide wire injury can be effectively improved through specific overexpression of the nuclear receptor binding protein 2 through smooth muscle cells, and it is prompted that the nuclear receptor binding protein 2 has a treatment effect and can serve as a marker to be applied to screening of drugs for treating postoperative restenosis neointimal hyperplasia.

The invention discloses a preparation method of an implantable artificial organ, the implantable artificial organ and application of the implantable artificial organ, and relates to the technical field of biomedical materials. The preparation method of the implantable artificial organ comprises the following steps: preparing zwitter-ion modified polyurethane from amphiphilic ion diol, monomer diol, diisocyanate, a catalyst, a chain extender and a reaction solvent through a solution polymerization method, dissolving the zwitter-ion modified polyurethane into a preparation solvent, and stirring to obtain the implantable artificial organ. The implantable artificial organ is prepared by a solution preparation method. According to the invention, bipolar ion diol is used as a hard segment, another monomer diol is used as a soft segment, and the influence of soft and hard segments with different molar ratios on the performance of the implantable artificial organ is studied. Wherein the hard segment can provide hydrophilicity, biocompatibility and antifouling property; the soft segment can provide flexibility and proper mechanical properties by regulating and controlling the molecular weight; diisocyanate is used as a chemical building block to connect soft and hard segments. The zwitter-ion modified polyurethane artificial blood vessel and heart valve prepared by the invention have good mechanical property, antifouling property and anticoagulation property, and the prepared artificial blood vessel also has the capability of resisting intimal hyperplasia and can keep unobstructed for a long time.

The invention provides an application of SENP5 in preparation of a medicine for treating intimal hyperplasia after vascular injury. Overexpression of SENP5 inhibits formation of neointima after vascular injury. The SENP5 disclosed by the invention can inhibit excessive proliferation and migration of vascular smooth muscle cells, effectively relieve intimal hyperplasia caused by carotid artery balloon injury and relieve narrow inner diameter of a blood vessel; sENP5 is taken as a target and is used for researching and developing vascular function protection medicines and intervention measures; the medicine is applied to clinical treatment of endometrial hyperplasia after vascular injury, and has wide application prospect and development value.

The invention relates to an internal arteriovenous fistula stent which comprises a base stent used for covering an arteriovenous anastomotic stoma area and a hybrid stent used for being arranged outside a to-be-anastomosed vein in a sleeving mode, the hybrid stent is of a net-shaped structure formed by composite weaving of degradable metal wires and non-degradable metal wires, the temporary supporting function of degradable materials is utilized, and the function of the hybrid stent is achieved. And a durable flexible framework is constructed by relying on non-degradable wires. The internal arteriovenous fistula stent can provide necessary constraint for blood vessels, especially anastomotic stoma areas in the early stage of a surgery so as to inhibit excessive expansion and intimal hyperplasia caused by abnormal stress, the degradable metal wires are gradually degraded along with gradual completion of vein artery remodeling, the stent can still maintain a complete net-shaped structure, and the stent has the advantages of being simple in structure and convenient to use. Meanwhile, the restraining effect can be gradually reduced, rigid restraining is avoided, and therefore the possibility that the stent structure loses efficacy and the blood vessel is restenosis is greatly reduced while the smoothness of the blood vessel is protected.

The invention provides a blood vessel expandable device and a preparation method, the blood vessel expandable device comprises a tubular stent body and a coating on the surface of the stent body, and the stent body has an expanded state and a compressed state; the coating at least comprises a middle layer on the surface of the stent body and a heparin membrane layer on the surface of the middle layer. According to the coating of the blood vessel expandable device, the middle layer serves as a link for connecting the heparin membrane layer and the blood vessel expandable device, the heparin membrane layer and the middle layer as well as the middle layer and the stent body can be in covalent bond and / or electrostatic adsorption connection, heparin can be completely or partially reserved on the device, and the coating is not prone to falling off; heparin in the coating, especially heparin with a certain content and low molecular weight, can control complications after implantation in stages after implantation, for example, the problem that thrombus easily occurs in the early stage can be better solved through the slow-release coating in the early stage, thrombus, intimal hyperplasia, stenosis and the like can be effectively controlled in the later stage, and endothelialization is promoted.

The invention relates to the technical field of biomedicine, in particular to application of a gene inhibitor in preparation of a medicine for preventing or treating restenosis after vascular injury. Specific knockdown or knockout of TRIM65 or MYH9 can inhibit formation of neointima, excessive intima neogenesis is the core pathological feature of restenosis after vascular injury, and therefore the TRIM65 inhibitor or MYH9 inhibitor can be used for preparing the medicine for preventing or treating restenosis after vascular injury.

The present invention relates to a method for manufacturing an implant material comprising core-shell structured nanofibers for preventing intimal hyperplasia. Nanofibers manufactured by a method for manufacturing core-shell structured nanofibers for preventing intimal hyperplasia and an implant material composition comprising same according to the present invention have the advantages of reducing thrombus formation, which can occur in artificial blood vessels upon initial implantation, and inducing rapid endothelialization. In addition, the implant material according to the present invention can be used for small-diameter peripheral or arterial blood vessel reconstruction and transplantation.

Methods of using a small molecule MYH11 agonist to inhibit intimal hyperplasia and to maintain a contractile phenotype in vitro and in vivo are described. Also described herein are methods for generating human contractile smooth muscle cells from human pluripotent stem cells under defined conditions in the presence of the small molecule MYH11 agonist.

The invention provides a bioactive nanogel coating on the surface of an intravascular stent as well as a preparation method and application of the bioactive nanogel coating. The coating is formed by blending a D-type phenylalanine derivative gel factor and a terminal REDV modified D-type phenylalanine derivative gel factor and can be self-assembled to form a stable nano spiral fiber-shaped gel coating structure, the unique extracellular matrix imitating structure and REDV can play a synergistic biological role, related protein adsorption is effectively regulated and controlled, and the application range is wide. Adhesion and proliferation of smooth muscle cells are remarkably inhibited; meanwhile, migration, adhesion and proliferation of vascular endothelial cells are selectively promoted, rapid re-endothelialization of the stent is achieved, and inflammation, thrombus, intimal hyperplasia and restenosis are inhibited. The component structure of the coating is bionic, the biocompatibility is excellent, the interface bonding force with a stent base body is good, the biological activity and effectiveness can be remarkably improved, the implantation degradation behavior of the degradable metal stent can be effectively regulated and controlled, and the biological safety is improved. Meanwhile, the preparation method of the coating is simple, convenient and feasible, and has a clinical transformation application prospect.

In one aspect, the disclosure relates to unimolecular micelles having N-hydroxysuccinimide ester (NHS), sulfo-NHS terminal groups, or other adhesive terminal groups, compositions including the same, methods of making the same, and methods of treating intimal hyperplasia in a subject using the same. In some aspects, the unimolecular micelles can further include fluorescent labels or drugs for treating intimal hyperplasia. In one aspect, the unimolecular micelles and compositions comprising the same are biocompatible, non-toxic, and non-inflammatory. In another aspect, the unimolecular micelles and compositions are substantially free from hydrogel, or are completely free from hydrogel. In still another aspect, the disclosed compositions and methods can be easily and quickly deployed in the operating room. Also disclosed is a method of applying the unimolecular micelles and compositions via direct penbrush painting.

The utility model relates to the technical field of medical intervention equipment, and provides an ultrasonic ablation device which comprises an ablation generating head and an ablation catheter. The ablation generation head comprises an ultrasonic transducer arranged in the ablation generation head and a peripheral balloon arranged on the peripheral part; one end of the ablation catheter is connected with the ablation generating head, and the other end is connected with the outdoor unit equipment; a pressure supply liquid path communicated with the peripheral balloon and a temperature control liquid path for controlling the temperature of the ablation generating head are arranged in the ablation catheter; an anti-skid positioning part is also arranged in the peripheral wall of the peripheral balloon; and the peripheral balloon can be expanded when the pressure supply liquid path is pressurized and can be retracted when the pressure supply liquid path is decompressed. The ultrasonic ablation device can be tightly attached to the inner wall of a pulmonary artery blood vessel of a patient through the anti-skid positioning part, the effect of accurately anchoring the ablation generating head and a to-be-ablated affected part is achieved, and real-time temperature control can be conducted on the ablation generating head through the temperature control liquid path; the problems of vascular intimal hyperplasia and stenosis caused by vascular wall injury due to ablation local high temperature are avoided.

The present invention discloses a new use of aspirin, specifically its use in the preparation of a drug for treating endometrial hyperplasia. In a model of estrogen-induced endometrial hyperplasia, aspirin effectively inhibits endometrial thickness in cynomolgus monkeys and mice. Aspirin significantly improves the symptoms of endometrial hyperplasia in both mice and cynomolgus monkeys, thus providing a new clinical application for aspirin.

The present invention provides the use of SENP5 in the preparation of a drug for treating intimal hyperplasia after vascular injury. Overexpression of SENP5 inhibits neointimal formation after vascular injury. The SENP5 described in the present invention can inhibit the excessive proliferation and migration of vascular smooth muscle cells, effectively reducing intimal hyperplasia caused by carotid artery balloon injury and alleviating vascular stenosis. Using SENP5 as a target, it can be used in the research and development of drugs and interventions to protect vascular function. Its application in the clinical treatment of intimal hyperplasia after vascular injury has broad application prospects and development value.

The present invention discloses a preparation method of a self-responsive coating for the whole process regulation and control tissue reaction of a cardiovascular implant interventional device, wherein 4-carboxylphenylboronic acid, carbodiimide and N-hydroxysuccinimide are dissolved in dimethyl sulfoxide at a molar ratio of 1:1.5:1.2, gelatin is added after sufficient reaction, deionized water is dialyzed, freeze-dried, and the product is dissolved in PBS to obtain a phenylboronic acid gelatin solution, which is then dropped into a mixed solution of polyphenol and dimethyl sulfoxide and fully reacted, and PBS is dialyzed to obtain a nanoparticle solution; the cardiovascular implant interventional device is immersed in an alkaline aqueous solution of dopamine to react, and after taking out and cleaning, it is sequentially immersed in a polycationic electrolyte solution, a nanoparticle solution, an antiplatelet drug, and an oxidized polysaccharide solution to react, and the reaction cycle is repeated multiple times. The coating prepared by the present invention can carry out whole process regulation and control, and the modified cardiovascular implant interventional device shows ideal endothelial regeneration and low intimal hyperplasia, thereby improving its function and long-term service rate.

The invention belongs to the technical field of minimally invasive interventional medical instruments, and discloses a medicine-carrying balloon catheter for treating pulmonary artery stenosis caused by takayasteritis, which comprises a handle, one end of the handle is fixedly connected with one end of a near-end rod, the other end of the near-end rod is fixedly connected with one end of a far-end rod, the other end of the far-end rod is fixedly connected with a balloon, and the balloon is fixedly connected with a catheter. The balloon is divided into a circular truncated cone shape and a cylindrical shape; the drug coating is arranged on the outer surface of the balloon, and the drug coating is used for carrying treatment drugs; the triangular wires are arranged on the outer side wall of the balloon in the length direction of the balloon. Through balloon dilatation and the micro-cutting effect of the triangular wire, the pulmonary artery stenosis part is effectively dilated, meanwhile, anti-inflammatory and anti-proliferation drugs are released in a targeted mode, inflammatory response and vascular intimal hyperplasia are inhibited, the restenosis occurrence rate is reduced, and the balloon dilatation triangular wire has the advantages of being high in safety and adaptability, remarkable in treatment effect and the like.

The application discloses a coated stent. The coated stent comprises a supporting framework and a degradable coated structure, the supporting framework is an elastic net structure, the coated structure comprises a wrapping piece and an elastic closed film piece, the wrapping piece is coated on the net wire of the supporting framework, and the elastic closed film piece is connected in each mesh of the supporting framework respectively, and the elastic closed film piece is used for closing the corresponding mesh. After the coated stent is implanted in a blood vessel, when the coated structure is degraded and absorbed, the vascular endothelium can carry out normal endothelialization process, in the treatment of vascular stenosis operation process, the coated stent can easily pass through the stenosis part of the blood vessel, and the risk of thrombosis in the coated stent and edge stenosis of the coated stent is reduced. The degradable coated structure made of biodegradable material is used for temporarily plugging the perforation, and the coated structure is degraded by the human body after a long time, so that the vascular restenosis is avoided, and the risk of vascular intimal hyperplasia is reduced.